To gain a more comprehensive understanding of the pharmacological effects of trastuzumab resistance and identify the optimal preclinical model for drug screening in combination therapy for GC, we utilized western blotting to identify HER2-positive GC cell lines, namely, NCI-N87 and SNU-216, among seven GC cell lines (Fig. 1a). Here, ERBB2 is linked to gastric cancer.